Cephalon Faces Class Cert. Bid In Actiq Marketing Row

Law360, New York (October 30, 2012, 8:25 PM EDT) -- Two companies that chip in for employees' prescription drugs sought class certification last week in a Pennsylvania suit against Cephalon over off-label marketing for the painkiller Actiq, saying the fact that potentially hundreds of companies had to pay for workers' prescriptions made the case suitable for class treatment.

The Indiana Carpenters Welfare Fund and the Pennsylvania Turnpike Commission are seeking $698.9 million – the profits they claim Cephalon made from illegally marketing Actiq, an opiate-based lollipop approved solely for breakthrough cancer pain, to other pain sufferers,...
To view the full article, register now.